Objective: We examined rates of adverse pregnancy outcomes (APO) by race/ethnicity among women with systemic lupus erythematosus (SLE), with and without antiphospholipid antibodies (aPL), and whether socioeconomic status (SES) accounted for differences.

Methods: Data were from the PROMISSE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study, a multicenter study that enrolled 346 patients with SLE and 62 patients with SLE and aPL (50% white, 20% African American, 17% Hispanic, 12% Asian/Pacific Islander). Measures of SES were educational attainment, median community income, and community education. Logistic regression analyses were conducted to determine odds of APO for each racial/ethnic group, controlling first for age and clinical variables, and then for SES.

Results: The frequency of APO in white women with SLE, with and without aPL, was 29% and 11%, respectively. For African American and Hispanic women it was approximately 2-fold greater. In African American women with SLE alone, adjustment for clinical variables attenuated the odds ratio (OR) from 2.7 (95% confidence interval [95% CI] 1.3-5.5) to 2.3 (95% CI 1.1-5.1), and after additional adjustment for SES, there were no longer significant differences in APO compared to whites. In contrast, in SLE patients with aPL, whites, African Americans, and Hispanics had markedly higher risks of APO compared to white SLE patients without aPL (OR 3.5 [95% CI 1.4-7.7], OR 12.4 [95% CI 1.9-79.8], and OR 10.4 [95% CI 2.5-42.4], respectively), which were not accounted for by clinical or SES covariates.

Conclusion: This finding suggests that for African American women with SLE without aPL, SES factors are key contributors to disparities in APO, despite monthly care from experts, whereas other factors contribute to disparities in SLE with aPL.

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23263DOI Listing

Publication Analysis

Top Keywords

sle apl
16
african american
16
systemic lupus
12
lupus erythematosus
12
sle patients
12
women sle
12
sle
9
socioeconomic status
8
adverse pregnancy
8
pregnancy outcomes
8

Similar Publications

We describe a patient with sickle cell disease (SCD) and elevated antiphospholipid antibodies (aPL) who developed multi-organ failure resembling catastrophic antiphospholipid syndrome. Autoimmune screening revealed several autoantibodies characteristic of systemic lupus erythematosus (SLE). Notably, routinely housed and unmanipulated transgenic sickle mice displayed significantly elevated titres of aPL- and SLE-associated autoantibodies.

View Article and Find Full Text PDF

Objective: Cardiovascular disease (CVD) is a leading cause of death in individuals with systemic lupus erythematosus (SLE). We assessed atherosclerotic plaque progression and incident cardiovascular events in patients with SLE over a 10-year follow-up.

Methods: We prospectively analyzed 738 carotid ultrasound measurements (413 in patients with SLE and 325 in age/sex-matched healthy controls [HCs]) to assess new plaque development from baseline to 3-, 7-, and 10-year follow-up.

View Article and Find Full Text PDF

Association Between Novel Antiphospholipid Antibodies and Adverse Pregnancy Outcomes.

Obstet Gynecol

January 2025

University of Utah and ARUP Laboratories, Salt Lake City, and Intermountain Health, Murray, Utah; the Hospital for Special Surgery, New York, New York; and Oregon Health & Science University, Portland, Oregon.

Objective: To investigate the value of anti-β2 glycoprotein-I domain 1 (aD1) and antiphosphatidylserine-prothrombin antibodies for predicting adverse pregnancy outcomes in an at-risk population and to describe the relationship among aD1, antiphosphatidylserine-prothrombin, lupus anticoagulant, and other antiphospholipid antibodies (aPL).

Methods: Data were obtained from a prospective cohort of pregnant patients with aPL, with systemic lupus erythematosus (SLE) (n=59) or without SLE (n=106), or SLE without aPL (n=100) (PROMISSE [Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus and Antiphospholipid Syndrome] study; NCT00198068). Levels of aD1 and antiphosphatidylserine-prothrombin were quantified with the QUANTA Flash and QUANTA Lite systems, respectively, in sera collected at less than 18 weeks of gestation.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the link between antiphospholipid antibodies (aPL) and diffuse alveolar hemorrhage (DAH) in patients with systemic lupus erythematosus (SLE) through a systematic review and meta-analysis.
  • Out of 454 studies reviewed, 9 were included, showing that SLE patients with positive aPL, especially lupus anticoagulant and anticardiolipin IgG, are more likely to experience DAH.
  • Additionally, having antiphospholipid syndrome (APS) increases the risk of DAH significantly compared to patients without APS.
View Article and Find Full Text PDF
Article Synopsis
  • * Out of 179 SLE patients studied, 55% reported headaches, with the most common types being tension-type (65%) and migraines (27%), while no lupus-specific headaches were identified.
  • * The study found that patients with headaches had higher disease activity scores and a notable association between migraines and the presence of antiphospholipid antibodies, although neurological issues were not statistically significant despite being more prevalent in the headache group.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!